MeTC7|cas:1817841-22-7|西域试剂

MeTC7,98.0%

产品编号：Bellancom-147337| CAS NO：1817841-22-7| 分子式：C₃₂H₄₈BrN₃O₄| 分子量：618.65

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-147337	￥1400.00	杭州北京（现货）
Bellancom-147337	￥2600.00	杭州北京（现货）
Bellancom-147337	￥5200.00	杭州北京（现货）
Bellancom-147337	￥8800.00	杭州北京（现货）
Bellancom-147337	￥15000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MeTC7

产品介绍

MeTC7 是一种维生素 D 受体 (VDR) 拮抗剂。MeTC7 具有有效的 VDR 抑制活性，IC₅₀ 值为 2.9 μM。MeTC7 显示出良好的抗肿瘤作用。

生物活性

MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC₅₀ value of 2.9 μM. MeTC7 shows good antitumor effects.

体外研究

MeTC7 (compound 5) shows potent VDR inhibition activity with an IC₅₀ value of 2.9 μM.
MeTC7 disrupts the VDR-Ligand-binding domain in Silico.
MeTC7 (250 nM; 18 h) suppresses RXRα and Importin-4 expressions in the ovarian cancer cell-line.
MeTC7 (250 nM; 18 h) inhibits the viability of ovarian cancer cells and induces PARP1 cleavage.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	2008 cells
Concentration:	250 nM
Incubation Time:	18, 12 h
Result:	Reduced the expression of RXR-α, Importin-4 and increased cleaved PARP1 expression in 2008 cells.

Cell Viability Assay

Cell Line:	SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines
Concentration:	0, 0.25, 0.5, 0.75, 1.0, 1.25 μM
Incubation Time:	24 h
Result:	Reduced the viability of SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines.

体内研究
(In Vivo)

MeTC7 (compound 5) (i.p.; 10 mg/kg) reduces the growth of the spontaneous transgenic TH-MYCN neuroblastoma and xenografts in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice
Dosage:	10 mg/kg
Administration:	IP
Result:	Reduced the growth of xenografts derived from ovarian cancer, medulloblastoma, and pancreatic cancer cells. Inhibited the growth of neuroblastoma cells and Xenografts. Reduced MYCN expression and blocked the growth of TH-MYCN transgene-driven spontaneous neuroblastoma.

体内研究

MeTC7 (compound 5) (i.p.; 10 mg/kg) reduces the growth of the spontaneous transgenic TH-MYCN neuroblastoma and xenografts in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice
Dosage:	10 mg/kg
Administration:	IP
Result:	Reduced the growth of xenografts derived from ovarian cancer, medulloblastoma, and pancreatic cancer cells. Inhibited the growth of neuroblastoma cells and Xenografts. Reduced MYCN expression and blocked the growth of TH-MYCN transgene-driven spontaneous neuroblastoma.

体内研究

MeTC7 (compound 5) (i.p.; 10 mg/kg) reduces the growth of the spontaneous transgenic TH-MYCN neuroblastoma and xenografts in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice
Dosage:	10 mg/kg
Administration:	IP
Result:	Reduced the growth of xenografts derived from ovarian cancer, medulloblastoma, and pancreatic cancer cells. Inhibited the growth of neuroblastoma cells and Xenografts. Reduced MYCN expression and blocked the growth of TH-MYCN transgene-driven spontaneous neuroblastoma.

性状

Solid

溶解性数据

In Vitro:

DMSO : 16.67 mg/mL (26.95 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6164 mL	8.0821 mL	16.1642 mL
5 mM	0.3233 mL	1.6164 mL	3.2328 mL
10 mM	0.1616 mL	0.8082 mL	1.6164 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.67 mg/mL (2.70 mM); Clear solution

此方案可获得 ≥ 1.67 mg/mL (2.70 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。